Seminars in Nuclear Medicine
Volume 34, Issue 1 , Pages 4-22 , January 2004

Impact of functional genomics and proteomics on radionuclide imaging

  • Uwe Haberkorn

      Affiliations

    • Department of Nuclear Medicine, University of Heidelberg, DKFZ, Heidelberg, Germany
    • Corresponding Author InformationAddress reprint requests to Uwe Haberkorn, MD, Department of Nuclear Medicine, University of Heidelberg, Im Neuenheimer Feld 400, FRG-69120, Heidelberg, Germany
    • ,
  • Annette Altmann

      Affiliations

    • Clinical Cooperation Unit Nuclear Medicine, DKFZ, Heidelberg, Germany
    • ,
  • Walter Mier

      Affiliations

    • Department of Nuclear Medicine, University of Heidelberg, DKFZ, Heidelberg, Germany
    • ,
  • Michael Eisenhut

      Affiliations

    • Department of Radiochemistry and Radiopharmacology, DKFZ, Heidelberg, Germany

References 

  1. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA. 1978;75:280–285
  2. Mukhopadhyay T, Tainsky M, Cavender AC, et al.  Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res. 1991;51:1744–1748
  3. Hannon GJ. RNA interference. Nature. 2002;418:244–251
  4. Zeng Y, Wagner EJ, Cullen BR, et al.  Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell. 2002;9:1327–1333
  5. Sui G, Soohoo C, Affar el B, et al.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A. 2002;99:5515–5520
  6. Moss EG. Silencing unhealthy alleles naturally. Trends Biotechnol. 2003;21:185–187
  7. Claverie JM. What if there are only 30,000 human genes?. Science. 2001;291:1255–1257
  8. Woolf TM, Melton DA, Jennings CGB. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci U S A. 1992;89:7305–7309
  9. Iversen PL, Zhu S, Meyer A, et al.  Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev. 1992;2:211–222
  10. Loke SL, Stein CA, Zhang XH, et al.  Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci U S A. 1989;86:3474–3478
  11. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al.  Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med. 1994;35:1054–1063
  12. Cammilleri S, Sangrajrang S, Perdereau B, et al.  Biodistribution of iodine-125 tyramine transforming growth factor alpha antisense oligonucleotide in athymic mice with a human mammary tumor xenograft following intratumoral injection. Eur J Nucl Med. 1996;23:448–452
  13. Kobori N, Imahori Y, Mineura K, et al.  Visualization of mRNA expression in CNS using 11C-labeled phosphorothioate oligodeoxynucleotide. Neuroreport. 1999;10:2971–2974
  14. Shi N, Boado RJ, Pardridge WM. Antisense imaging of gene expression in the brain in vivo. Proc Natl Acad Sci U S A. 2000;97:14709–14714
  15. Urbain JL, Shore SK, Vekemans MC, et al.  Scintigraphic imaging of oncogenes with antisense probes (Does it make sense?). Eur J Nucl Med. 1995;22:499–504
  16. Tavitian B, Terrazzino S, Kühnast B, et al.  In vivo imaging of oligonucleotides with positron emission tomography. Nature Med. 1998;4:467–471
  17. Watanabe N, Sawai H, Endo K, et al.  Labeling of phosphorothioate antisense oligonucleotides with yttrium-90. Nucl Med Biol. 1999;26:239–243
  18. Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis. 1977;18:533–537
  19. Futcher B, Latter GI, Monardo P, et al.  A sampling of the yeast proteome. Mol Cell Biol. 1999;19:7357–7368
  20. Gygi SP, Rist B, Gerber SA, et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol. 1999;17:994–999
  21. Pradet-Balade B, Boulme F, Beug H, et al.  Translation control (Bridging the gap between genomics and proteomics?). Trends Biochem Sci. 2001;26:225–229
  22. Claverie JM. Computational methods for the identification of differential and coordinated gene expression. Hum Mol Genet. 1999;8:1821–1832
  23. Werner T. Models for prediction and recognition of eukaryotic promoters. Mamm Genome. 1999;10:168–175
  24. Wouters FS, Verveer PJ, Bastiaens PIH. Imaging biochemistry inside cells. Trends Cell Biol. 2001;11:203–211
  25. Alauddin MM, Shahinian A, Kundu RK, et al.  Evaluation of 9-[(3-18F-fluoro-1-hydroxy-2-propoxy)methyl]guanine ([18F]-FHPG) in vitro and in vivo as a probe for PET imaging of gene incorporation and expression in tumors. Nucl Med Biol. 1999;26:371–376
  26. De Vries EF, van Waarde A, Harmsen MC, et al.  [11C]FMAU and [18F]FHPG as PET tracers for herpes simplex virus thymidine kinase enzyme activity and human cytomegalovirus infections. Nucl Med Biol. 2000;27:113–119
  27. Gambhir SS, Barrio JR, Phelps ME, et al.  Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci U S A. 1999;96:2333–2338
  28. Haberkorn U, Altmann A, Morr I, et al.  Gene therapy with Herpes Simplex Virus thymidine kinase in hepatoma cells (Uptake of specific substrates). J Nucl Med. 1997;38:287–294
  29. Haberkorn U, Khazaie K, Morr I, et al.  Ganciclovir uptake in human mammary carcinoma cells expressing Herpes Simplex Virus thymidine kinase. Nucl Med Biol. 1998;25:367–373
  30. Haberkorn U, Altmann A. Imaging methods in gene therapy of cancer. Current Gene Ther. 2001;1:163–182
  31. Haubner R, Avril N, Hantzopoulos PA, et al.  In vivo imaging of herpes simplex virus type 1 thymidine kinase gene expression (early kinetics of radiolabelled FIAU). Eur J Nucl Med. 2000;27:283–291
  32. Hospers GA, Calogero A, van Waarde A, et al.  Monitoring of herpes simplex virus thymidine kinase enzyme activity using positron emission tomography. Cancer Res. 2000;60:1488–1491
  33. Hustinx R, Shiue CY, Alavi A, et al.  Imaging in vivo herpes simplex virus thymidine kinase gene transfer to tumour-bearing rodents using positron emission tomography and (18F)FHPG. Eur J Nucl Med. 2001;28:5–12
  34. Jacobs A, Voges J, Reszka R, et al.  Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001;358:727–729
  35. Monclus M, Luxen A, Van Naemen J, et al.  Development of PET radiopharmaceuticals for gene therapy (Synthesis of 9-((1-(18F)fluoro-3-hydroxy-2-propoxy)methyl)guanine). J Label Compd Radiopharm. 1995;37:193–195
  36. Saito Y, Price RW, Rottenberg DA, et al.  Quantitative autoradiographic mapping of herpes simplex virus encephalitis with radiolabeled antiviral drug. Science. 1982;217:1151–1153
  37. Tjuvajev JG, Stockhammer G, Desai R, et al.  Imaging the expression of transfected genes in vivo. Cancer Res. 1995;55:6126–6132
  38. Tjuvajev JG, Avril N, Oku T, et al.  Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 1998;58:4333–4341
  39. Wiebe LI, Knaus EE, Morin KW, et al.  Radiolabelled pyrimidine nucleosides to monitor the expression of HSV-1 thymidine kinase in gene therapy. Nucleosides Nucleotides. 1999;18:1065–1066
  40. Gambhir SS, Bauer E, Black ME, et al.  A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A. 2000;97:2785–2790
  41. MacLaren DC, Gambhir SS, Satyamurthy N, et al.  Repetitive non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther. 1999;6:785–791
  42. Zinn KR, Buchsbaum DJ, Chaudhuri TR, et al.  Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re. J Nucl Med. 2000;41:887–895
  43. Raben D, Buchsbaum DJ, Khazaeli MB, et al.  Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther. 1996;3:567–580
  44. Bogdanov A, Simonova M, Weissleder R. Design of metal-binding green fluorescent protein variants. Biochim Biophys Acta. 1998;1397:56–64
  45. Simonova M, Weissleder R, Sergeyev N, et al.  Targeting of green fluorescent protein expression to the cell surface. Biochem Biophys Res Commun. 1999;62:638–642
  46. Boland A, Magnon C, Filetti S, et al.  Transposition of the thyroid iodide uptake and organification system in nonthyroid tumor cells by adenoviral vector-mediated gene transfers. Thyroid. 2002;12:19–26
  47. Carlin S, Cunningham SH, Boyd M, et al.  Experimental targeted radioiodide therapy following transfection of the sodium iodide symporter gene (Effect on clonogenicity in both two-and three-dimensional models). Cancer Gene Ther. 2000;7:1529–1536
  48. Cho JY, Xing S, Liu X, et al.  Expression and activity of human Na+/I- symporter in human glioma cells by adenovirus-mediated gene delivery. Gene Ther. 2000;7:740–749
  49. Haberkorn U, Henze M, Altmann A, et al.  Transfer of the human sodium iodide symporter gene enhances iodide uptake in hepatoma cells. J Nucl Med. 2001;42:317–325
  50. Haberkorn U, Kinscherf R, Kissel M, et al.  Enhanced iodide transport after transfer of the human sodium iodide symporter gene is associated with lack of retention and low absorbed dose. Gene Ther. 2003;10:774–780
  51. La Perle KM, Shen D, Buckwalter TL, et al.  In vivo expression and function of the sodium iodide symporter following gene transfer in the MATLyLu rat model of metastatic prostate cancer. Prostate. 2002;50:170–178
  52. Mandell RB, Mandell LZ, Link CJ. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res. 1999;59:661–668
  53. Nakamoto Y, Saga T, Misaki T, et al.  Establishment and characterization of a breast cancer cell line expressing Na+/I− symporters for radioiodide concentrator gene therapy. J Nucl Med. 2000;41:1898–1904
  54. Shimura H, Haraguchi K, Miyazaki A, et al.  Iodide uptake and experimental 131J therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I− symporter gene. Endocrinology. 1997;138:4493–4496
  55. Sieger S, Jiang S, Schönsiegel F, et al.  Tumour specific activation of the sodium/iodide symporter gene under control of the glucose transporter gene 1 promoter (GTI-1.3). Eur J Nucl Med. 2003;30:748–756
  56. Smit JW, Shroder-van der Elst JP, Karperien M, et al.  Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line. Thyroid. 2000;10:939–943
  57. Smit JWA, Schroder-van der Elst JP, Karperien M, et al.  Iodide kinetics and experimental 131I therapy in a xenotransplanted human sodium-iodide symporter-transfected human follicular thyroid carcinoma cell line. J Clin Endocrinol Metab. 2002;87:1247–1253
  58. Spitzweg C, O’Connor MK, Bergert ER, et al.  Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res. 2000;60:6526–6530
  59. Spitzweg C, Dietz AB, O’Connor MK, et al.  In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 2001;8:1524–1531
  60. Haberkorn U, Altmann A, Eisenhut M. Functional genomics and proteomics-The role of nuclear medicine. Eur J Nuc Med. 2002;29:115–132
  61. Oliver FJ, Collins MKL, Lopez-Rivas A. Overexpression of a heterologous thymidine kinase delays apoptosis induced by factor deprivation and inhibitors of deoxynucleotide metabolism. J Biol Chem. 1997;272:10624–10630
  62. Liang Q, Satyamurthy N, Barrio JR, et al.  Noninvasive and quantitative imaging, in living animals, of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther. 2001;19:1490–1498
  63. Tucker CL, Gera JF, Uetz P. Towards an understanding of complex protein networks. Trends Cell Biol. 2001;11:102–106
  64. Marcotte EM, Pellegrini M, Ng HL, et al.  Detecting protein function and protein-protein interactions from genome sequences. Science. 1999;285:751–753
  65. Wouters FS, Verveer PJ, Bastiaens PIH. Imaging biochemistry inside cells. Trends Cell Biol. 2001;11:203–211
  66. Ray P, Pimenta H, Paulmurugan R, et al.  Noninvasive quantitative imaging of protein-protein interactions in living subjects. Proc Natl Acad Sci U S A. 2002;99:3105–3110
  67. Wu JC, Sundaresan G, Iyer M, et al.  Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther. 2001;4:297–306
  68. Luker GD, Sharma V, Pica CM, et al.  Noninvasive imaging of protein-protein interactions in living animals. Proc Natl Acad Sci U S A. 2002;99:6961–6966
  69. Rossi FMV, Blakely BT, Blau HM. Interaction blues (Protein interactions monitored in live mammalian cells by β-galactosidase complementation). Trends Cell Biol. 2000;10:119–122
  70. Mills KV, Paulus H. Reversible inhibition of protein splicing by zinc ion. J Biol Chem. 2001;276:10832–10838
  71. Gimble FS. Putting protein splicing to work. Chem Biol. 1998;5:R251–R256
  72. Paulmurugan R, Umezawa Y, Gambhir SS. Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies. Proc Natl Acad Sci U S A. 2002;99:15608–15613
  73. Werner T. Promoters can contribute to the elucidation of protein function. Trends Biotechnol. 2003;21:9–13
  74. Haberkorn U, Altmann A. Noninvasive imaging of protein-protein interaction in living organisms. Trends Biotechnol. 2003;21:241–243
  75. Jiang S, Altmann A, Grimm D, et al.  Tissue-specific gene expression in medullary thyroid carcinoma cells employing calcitonin regulatory elements and AAV vectors. Cancer Gene Ther. 2001;8:469–472
  76. Iyer M, Wu L, Carey M, et al.  Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A. 2001;98:14595–14600
  77. Harrison LH, Schwarzenberger PO, Byrne PS, et al.  Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg. 2000;70:407–411
  78. Gupta S, Lee CD, Vemuru RP, et al.  111Indium labeling of hepatocytes for analysis of short-term biodistribution of transplanted cells. Hepatology. 1994;19:750–757
  79. Josephson L, Tung CH, Moore A, et al.  High-efficiency intracellular magnetic labeling with novel supermagnetic-tat peptide conjugates. Bioconjugate Chem. 1999;10:186–191
  80. Schellingerhout D, Bogdanov A, Marecos E, et al.  Mapping the in vivo distribution of herpes simplex virions. Hum Gene Ther. 1998;9:1543–1549
  81. Zinn KR, Douglas JT, Smyth CA, et al.  Imaging and tissue biodistribution of 99mTc-labeled adenovirus knob (serotype 5). Gene Ther. 1998;5:798–808
  82. Altmann A, Haberkorn U. Assessment of gene transfer using imaging methodology. Curr Genomics. 2003;4:167–184
  83. Germann C, Shields AF, Grierson JR, et al.  5-Fluoro-1-(2′-deoxy-2′-fluoro-β-D-ribofuranosyl)uracil trapping in Morris hepatoma cells expressing the Herpes Simplex Virus thymidine kinase gene. J Nucl Med. 1998;39:1418–1423
  84. Mahony WB, Domin BA, McConnell RT, et al.  Acyclovir transport into human erythrocytes. J Biol Chem. 1988;263:9285–9291
  85. Gati WP, Misra HK, Knaus EE, et al.  Structural modifications at the 2′ and 3′ positions of some pyrimidine nucleosides as determinants of their interaction with the mouse erythrocyte nucleoside transporter. Biochem Pharmacol. 1984;33:3325–3331
  86. Haberkorn U, Oberdorfer F, Gebert J, et al.  Monitoring of gene therapy with cytosine deaminase (In vitro studies using 3H-5-fluorocytosine). J Nucl Med. 1996;37:87–94
  87. Haberkorn U. Monitoring of gene transfer for cancer therapy with radioactive isotopes. Ann Nucl Med. 1999;13:369–377
  88. Hamstra DA, Rice DJ, Fahmy S, et al.  Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther. 1999;10:1993–2003
  89. Stegman LD, Rehemtulla A, Beattie B, et al.  Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 1999;96:9821–9826
  90. Marcocci C, Cohen JL, Grollman EF. Effect of actinomycin D on iodide transport in FRTL-5 thyroid cells. Endocrinology. 1984;115:2123–2132
  91. Weiss SJ, Philp NJ, Grollman EF. Iodide transport in a continuous line of cultured cells from rat thyroid. Endocrinology. 1984;114:1090–1098
  92. Paire A, Bernier-Valentin F, Selmi-Ruby S, et al.  Characterization of the rat thyroid iodide transporter using anti-peptide antibodies. J Biol Chem. 1997;272:18245–18249
  93. Nakamura Y, Ohtaki S, Yamazaki I. Molecular mechanism of iodide transport by thyroid plasmalemmal vesicles (Cooperative sodium activation and asymmetrical affinities for the ions on the outside and inside of the vesicles). J Biochem. 1988;104:544–549
  94. Nakamura Y, Kotani T, Ohtaki S. Transcellular iodide transport and iodination on the apical plasma membrane by monolayer porcine thyroid cells cultured on collagen-coated fibers. J Endocrin. 1990;126:275–281
  95. Smanik PA, Liu Q, Furminger TL, et al.  Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun. 1996;226:339–345
  96. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458–460
  97. Huang M, Batra RK, Kogai T, et al.  Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther. 2001;8:612–618
  98. Berman M, Hoff E, Barandes M. Iodine kinetics in man (A model). J Clin Endocrinol Metab. 1968;28:1–14
  99. Maxon HR, Thomas SR, Hertzberg VS, et al.  Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–941
  100. Haberkorn U, Altmann A, Jiang S, et al.  Iodide uptake in human anaplastic thyroid carcinoma cells after transfer of the human thyroid peroxidase gene. Eur J Nucl Med. 2001;28:633–638
  101. Koong SS, Reynolds JC, Movius EG, et al.  Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1999;84:912–916
  102. Urabe M, Hershman JM, Pang XP, et al.  Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology. 1991;129:807–814
  103. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid. 1998;8:909–913
  104. Sedvall G, Jonsson B, Petterson U, et al.  Effects of lithium salts on plasma protein bound iodine and uptake of 131I in thyroid gland of man and rat. Life Sci. 1968;7:1257–1264
  105. Temple R, Berman M, Robbins J, et al.  The use of lithium in the treatment of thyrotoxicosis. J Clin Invest. 1972;51:2746–2756
  106. Gershengorn MC, Izumi M, Robbins J. Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma. J Clin Endocrinol Metab. 1976;42:105–111
  107. Dadachova E, Bouzahzah B, Zuckier LS, et al.  Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol. 2002;29:13–18
  108. Petrich T, Helmeke HJ, Meyer GJ, et al.  Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium iodide symporter. Eur J Nucl Med. 2002;29:842–854
  109. Smets LA, Loesberg C, Janssen M, et al.  Active uptake and extravesicular storage of m-iodobenzyl guanidine in human neuroblastoma. Cancer Res. 1989;49:2941–2944
  110. Wafelman AR, Hoefnagel CA, Maes RAA, et al.  Radioiodinated metaiodo-benzylguanidine (A review of its distribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry). Eur J Nucl Med. 1994;21:545–559
  111. Mairs RJ, Livingstone A, Gaze MN, et al.  A Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer. 1994;70:97–101
  112. Glowniak JV, Kilty JE, Amara SG, et al.  Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med. 1993;34:1140–1146
  113. Lode HN, Bruchelt G, Seitz G, et al.  Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines (Correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression). Eur J Cancer. 1995;31A:586–590
  114. Pacholczyk T, Blakely RD, Amara SG. Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature. 1991;350:350–354
  115. Boyd M, Cunningham SH, Brown MM, et al.  Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine. Gene Ther. 1999;6:1147–1152
  116. Altmann A, Kissel M, Zitzmann S, et al.  Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med. 2003;44:973–980
  117. Bomanji J, Levison DA, Flatman WD, et al.  Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas (A histopathological comparison). J Nucl Med. 1987;28:973–978
  118. Ryu DDY, Nam DH. Recent progress in biomolecular engineering. Biotechnol Prog. 2000;16:2–16
  119. Anderson NL, Anderson NG. Proteome and proteomics (New technologies, new concepts, and new words). Electrophoresis. 1998;19:1853–1861
  120. Ohkubo N, Mitsuda N, Tamatani M, et al.  Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. J Biol Chem. 2000;276:3046–3053
  121. Morin KW, Knaus EE, Wiebe LI, et al.  Reporter gene imaging (Effects of ganciclovir treatment on nucleoside uptake, hypoxia and perfusion in a murine gene therapy tumour model that expresses herpes simplex type-1 thymidine kinase). Nucl Med Commun. 2000;21:129–137
  122. Haberkorn U, Altmann A, Morr I, et al.  Multi tracer studies during gene therapy of hepatoma cells with HSV thymidine kinase and ganciclovir. J Nucl Med. 1997;38:1048–1054
  123. Haberkorn U, Bellemann ME, Gerlach L, et al.  Uncoupling of 2-fluoro-2-deoxyglucose transport and phosphorylation in rat hepatoma during gene therapy with HSV thymidine kinase. Gene Ther. 1998;5:880–887
  124. Haberkorn U, Altmann A, Kamencic H, et al.  Glucose transport and apoptosis after gene therapy with HSV thymidine kinase. Eur J Nucl Med. 2001;28:1690–1696
  125. Martin SJ, Reutelingsperger CPM, McGahon AJ. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus (Inhibition by overexpression of Bcl-2 and Abl). J Exp Med. 1995;182:1545–1556
  126. Villa P, Kaufmann SH, Earnshwa WC. Caspases and caspase inhibitors. Trends Biochem Sci. 1997;22:388–393
  127. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1998;89:1121–1132
  128. Blankenberg FG, Katsikis PD, Tait JF, et al.  In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A. 1998;95:6349–6354
  129. Blankenberg FG, Katsikis PD, Tait JF, et al.  Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med. 1999;40:184–191
  130. Haberkorn U, Kinscherf R, Krammer PH, et al.  Investigation of a potential scintigraphic marker of apoptosis (Radioiodinated Z-Val-Ala-DL-Asp(O-Methyl)-fluoromethyl ketone). Nucl Med Biol. 2001;28:793–798
  131. Stemmer WPC. Rapid evolution of protein in vitro by DNA shuffling. Nature. 1994;370:389–391
  132. Kolkman JA, Stemmer WPC. Directed evolution of proteins by exon shuffling. Nature Biotechnol. 2001;19:423–428
  133. Zwick MB, Shen J, Scott JK. Phage-displayed peptide libraries. Curr Opin Biotechnol. 1998;9:427–436
  134. Smithgall TE. SH2 and SH3 domains (Potential targets for anti-cancer drug design). J Pharmacol Toxicol Methods. 1995;34:125–132
  135. Arnold FH. Combinatorial and computational challenges for biocatalyst design. Nature. 2001;409:253–257
  136. Ohlstein EH, Ruffolo RR, Elliott JD. Drug discovery in the next millennium. Annu Rev Pharmacol Toxicol. 2000;40:177–191

PII: S0001-2998(03)00069-2

doi: 10.1053/j.semnuclmed.2003.09.003

Seminars in Nuclear Medicine
Volume 34, Issue 1 , Pages 4-22 , January 2004

Article Tools

* Image Usage & Resolution